ArticleActa diabetologica2026
Trends in prevalence of chronic kidney disease and risk management among US adults with diabetes, 2001 to 2020.
Article in Acta diabetologica, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
aimsTo examine trends in prevalence of chronic kidney disease (CKD) and risk management among US adults with diabetes between 2001 and 2020. METHODS AND
resultsThis serial cross-sectional study included 4200 adults with diabetes (representing approximately 29.0 million persons) from the National Health and Nutrition Examination Survey (2001 to 2020). Age-adjusted prevalence of CKD G3a among adults with diabetes decreased from 6.6% to 3.0% by 2005-2008, then plateaued. CKD G4-G5 increased from 0.5% to 1.7% by 2009-2012, then decreased to 0.7% by 2017-2020. The prevalence of any CKD decreased from 34.1% to 25.3% by 2009-2012, then increased to 30.6% by 2017-2020. Correspondingly, albuminuria decreased from 28.4% to 21.2% by 2009-2012, then increased to 27.4% by 2017-2020. Among adults with concomitant CKD, proportion of adults achieving blood pressure (BP) < 140/90 mmHg increased from 64.6% to 75.1% by 2005-2008, then decreased to 59.5% by 2017-2020. Low-density lipoprotein cholesterol < 100 mg/dL, non-high-density lipoprotein cholesterol < 130 mg/dL, antidiabetic medication use and antihyperlipidemic medication use increased from 30.4%, 22.8%, 58.6%, and 33.8% to 46.4%, 45.6%, 74.2%, and 38.8%, respectively. Recommended antidiabetic medication use decreased from 37.6% to 24.2% by 2009-2012, then increased to 59.2% by 2017-2020.
conclusionsAfter a decade of decline, the prevalence of any CKD and albuminuria increased among US adults with diabetes, while CKD G3a plateaued. CKD G4-G5 peaked during 2005-2012 and decreased thereafter. Lipid control and use of antidiabetic and antihyperlipidemic medications among adults with concomitant CKD increased in the past 2 decades, whereas BP control decreased. This study provided updated trends in the prevalence of chronic kidney disease (CKD) in diabetes and in risk factor control and medication use in diabetes and CKD by using a nationally representative sample of the whole US noninstitutionalized population. Among US adults with diabetes, the prevalence of CKD decreased in earlier years but increased in recent years, while improvements in medication use for diabetes and lipids were observed, though blood pressure control declined.
Indexed as
Identifiers
41240072What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.